PCM
CHRS icon

Peregrine Capital Management’s Coherus Oncology CHRS Stock Holding History

Peregrine Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-734,877
Closed -$764K – 336
2024
Q3 		$764K Sell
734,877
-277,758
-27% -$381K 0.02% 277
2024
Q2 		$1.75M Sell
1,012,635
-3,820
-0.4% -$7.69K 0.05% 252
2024
Q1 		$2.43M Sell
1,016,455
-73,506
-7% -$181K 0.07% 247
2023
Q4 		$3.63M Sell
1,089,961
-288,606
-21% -$773K 0.11% 241
2023
Q3 		$5.16M Sell
1,378,567
-58,986
-4% -$272K 0.15% 227
2023
Q2 		$6.14M Buy
1,437,553
+370,369
+35% +$2.19M 0.17% 229
2023
Q1 		$7.3M Sell
1,067,184
-50,298
-5% -$390K 0.21% 206
2022
Q4 		$8.85M Sell
1,117,482
-12,124
-1% -$93.3K 0.28% 162
2022
Q3 		$10.9M Buy
1,129,606
+52,321
+5% +$529K 0.35% 87
2022
Q2 		$7.8M Buy
1,077,285
+130,226
+14% +$1.13M 0.24% 191
2022
Q1 		$12.2M Buy
947,059
+206,139
+28% +$2.62M 0.29% 119
2021
Q4 		$11.8M Sell
740,920
-136,365
-16% -$2.38M 0.24% 156
2021
Q3 		$14.1M Sell
877,285
-180,589
-17% -$2.65M 0.29% 118
2021
Q2 		$14.6M Buy
1,057,874
+187,151
+21% +$2.65M 0.26% 169
2021
Q1 		$12.7M Sell
870,723
-31,064
-3% -$527K 0.24% 211
2020
Q4 		$15.7M Buy
901,787
+376,895
+72% +$6.71M 0.3% 144
2020
Q3 		$9.63M Buy
524,892
+79,635
+18% +$1.48M 0.26% 138
2020
Q2 		$7.95M Buy
445,257
+6,366
+1% +$108K 0.23% 146
2020
Q1 		$7.12M Sell
438,891
-4,971
-1% -$91.8K 0.26% 132
2019
Q4 		$7.99M Buy
443,862
+206,771
+87% +$3.81M 0.2% 173
2019
Q3 		$4.8M Buy
+237,091
New +$4.74M 0.13% 227

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Peregrine Capital Management's CHRS Position: Q4 2024 in Review

Peregrine Capital Management sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 734,877 shares — an estimated $764K sold.

Peregrine Capital Management first reported a position in CHRS in Q3 2019 and held it in 21 quarters. The position peaked at $15.7M in Q4 2020. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

  • Peregrine Capital Management reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
  • Peregrine Capital Management sold 734,877 Coherus Oncology shares in Q4 2024, an estimated $764K.
  • Peregrine Capital Management first reported a position in Coherus Oncology in Q3 2019 and held it in 21 quarters.
  • Peregrine Capital Management's Coherus Oncology position peaked at $15.7M in Q4 2020.
  • 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on Peregrine Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.